Quick Take
Nurix Therapeutics (NRIX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing small molecule-based treatments for blood cancers and immune system conditions.
NRIX is a promising biopharma with substantial major pharma partnerships, but has yet to enter Phase 1 safety trials for its lead candidate, so the firm and IPO is ultra high risk.
I’ll provide a final opinion when we learn more about the IPO from management.
Company & Technology
San Francisco, California-based Nurix was founded